生物技术通报 ›› 2023, Vol. 39 ›› Issue (7): 316-324.doi: 10.13560/j.cnki.biotech.bull.1985.2022-1418

• 研究报告 • 上一篇    下一篇

瑞香狼毒降低YAP1表达抑制肝癌细胞增殖的作用

周文汉(), 郑康宁, 李永民()   

  1. 河北中医学院,石家庄 050200
  • 收稿日期:2022-11-16 出版日期:2023-07-26 发布日期:2023-08-17
  • 通讯作者: 李永民,男,博士,教授,研究方向:中医药抗肿瘤;E-mail: liyongmin2001@sina.com
  • 作者简介:周文汉,男,硕士研究生,研究方向:中医药抗肿瘤;E-mail: 617982358@qq.com
  • 基金资助:
    河北省高等学校科学技术研究项目(ZD2021077);河北中医学院2021年研究生创新资助项目(XCXZZSS2021014)

Stellera chamaejasme L. Inhibiting Cell Proliferation by Reducing YAP1 Expression in Hepatocellular Carcinoma

ZHOU Wen-han(), ZHENG Kang-ning, LI Yong-min()   

  1. Heibei University of Chinese Medicine, Shijiazhuang 050200
  • Received:2022-11-16 Published:2023-07-26 Online:2023-08-17

摘要:

探讨瑞香狼毒(Stellera chamaejasme L., SCL)抑制肝癌细胞增殖的效应和机制,为原发性肝细胞癌的病理机制研究和临床治疗提供依据。SCL含药血清处理HepG2215细胞24 h,CCK-8法分析肝癌HepG2215细胞增殖活力。Western blot分析肝癌HepG2215细胞中Yes关联蛋白1(yes-associated protein 1,YAP1)表达的情况;应用N-亚硝基二乙胺(diethylnirtosamine,DEN)/组成型雄甾烷受体激动剂(3,5-dichloro-2-[4-(3,5-dichloropyridin-2-yl)oxyphenoxy]pyridine,TCPOBOP)诱导肝细胞特异性Yap1敲除(Yap1LKO)小鼠和Yap1flox/flox小鼠构建肝原位癌模型;SCL水煎液灌胃7 d,取出肝脏,观察肝脏肿瘤大体形态;H&E染色观察肝脏肿瘤组织病理形态,Western blot分析肝脏肿瘤组织中YAP1的表达。细胞试验结果表明,SCL抑制HepG2215细胞的增殖,并降低了YAP1的表达水平。动物试验结果表明,SCL能减小Yap1flox/floxYap1LKO小鼠肝原位癌肿瘤体积和肝肿瘤中YAP1的表达水平。在NS组中,与Yap1flox/flox小鼠相比,Yap1LKO小鼠肝原位癌肿瘤体积减小了。在SCL组中,与Yap1flox/flox小鼠相比,Yap1敲除减弱了SCL抑制肿瘤增长的作用。利用LC-MS检测SCL含药血清和水煎液的活性成分,并与YAP1蛋白进行分子对接。LC-MS结果显示,SCL的4种活性成分是3-硫酸咖啡酸、5-苄恶唑-2-酮、3,4,5-三羟基-6-[(2-氧代-2H-铬-5-基)氧]氧烷-2-羧酸和异东莨菪内酯。其中,3-硫酸咖啡酸、3,4,5-三羟基-6-[(2-氧代-2H-铬-5-基)氧]氧烷-2-羧酸和异东莨菪内酯这3种主要活性成分能直接结合YAP1。这些结果说明,SCL抑制肝癌细胞增殖与降低YAP1表达有关。

关键词: 瑞香狼毒, HepG2215细胞, 原发性肝细胞癌, YAP1

Abstract:

This study is to investigate the effect and mechanism of Stellera chamaejasme L.(SCL)on inhibiting proliferation of hepatocellular carcinoma cells, providing basis for the pathological mechanism study and clinical treatment of primary hepatocellular carcinoma. Firstly, CCK-8 assay was performed to illustrate the ability of tumor growth in the HepG2215 cells treated with SCL serum containing blood. Western blot was used to detect the expression of YAP1(yes-associated protein 1)protein in the HepG2215 cells. Secondly, Yap1flox/flox and Yap1LKO mice were induced to form liver tumors in situ by DEN(diethylnirtosamine)/TCPOBOP(3,5-dichloro-2-[4-(3,5-dichloropyridin-2-yl)oxyphenoxy]pyridine). SCL decoction was given to the stomach of the mice for 7 d, the liver was taken out, and the general shape of the liver tumor was observed. H&E was performed to observe the pathological morphology in tumor tissue. Western blot was to detect the expressions of YAP1 in the liver tumor tissues. The results from cell experiment demonstrated that SCL inhibited the proliferation of HepG2215 cells and decreased YAP1 expression. Moreover, animal experiment revealed that SCL reduced tumor volume and YAP1 expression both in Yap1flox/flox and Yap1LKO mice with tumors in liver. The hepatocellular carcinoma tumor volume of Yap1LKO mice in NS group reduced when compared with Yap1flox/flox mice. Yap1 knockdown reduced the effect of SCL inhibiting tumor growing in SCL group when compared with Yap1flox/flox mice. LC-MS was used to detect the active components of SCL drug-containing serum and water decoction, and molecular docking was carried out with YAP1 protein. LC-MS results showed that the active ingredients were caffeic acid 3-sulfate, 5-benzyloxolan-2-one, 3,4,5-trihydroxy-6-[(2-oxo-2h-chromen-5-yl)oxy]oxane-2-carboxylic acid and isoscopoletin in SCL. Among them, caffeic acid 3-sulfate, 3,4,5-trihydroxy-6-[(2-oxo-2h-chromen-5-yl)oxy]oxane-2-carboxylic acid and isoscopoletin directly formed stable docking with YAP1 protein. These results suggest that SCL inhibits liver tumor cell proliferation by reducingYAP1 expression.

Key words: Stellaria chamaejasme L., HepG2215 cells, hepatocellular carcinoma, YAP1